Company
Headquarters: Zhengzhou, China
CN¥3.25 Billion
CNY as of Jan. 1, 2025
US$445.9 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Henan Taloph Pharmaceutical Stock Co., Ltd. researches, produces, and sells Chinese and western medicines in China. It primarily offers its products in the forms of oral liquids, tablets, capsules, fluids, and other forms. The company's principal products include Huperzine A tablets, phenoxybenzamine hydrochloride tablets, pazufloxacin mesylate sodium chloride injections, and various infusion products. It serves hospitals, pharmacies, and patients. The company was formerly known as Henan Joyline & Joysun Pharmaceutical Stock Co., Ltd. Henan Taloph Pharmaceutical Stock Co., Ltd. is based in Zhengzhou, China.
Henan Taloph Pharmaceutical Stock Co.,Ltd has the following listings and related stock indices.
Stock: SSE: 600222 wb_incandescent